Recordati Industria Chimica e Farmaceutica S.p.A. (LON: 0KBS)

Market Cap	9.64B
Revenue (ttm)	1.89B
Net Income (ttm)	352.10M
Shares Out	n/a
EPS (ttm)	1.68
PE Ratio	27.38
Forward PE	n/a
Dividend	1.04 (1.89%)
Ex-Dividend Date	Nov 18, 2024

Volume	7,055
Average Volume	9,020
Open	54.90
Previous Close	55.00
Day's Range	55.20 - 55.85
52-Week Range	39.18 - 45.39
Beta	0.40
RSI	72.01
Earnings Date	Feb 21, 2025

About Recordati Industria Chimica e Farmaceutica

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceuticals in Italy and internationally. It operates through Specialty and Primary Care and Rare Diseases segments. The company’s product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing’s syndrome; and CYSTADROPS for the treatment of cystine crystal deposits...

• Industry: Pharmaceutical Preparations
• Founded: 1926
• Employees: 4,455
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0KBS

Financial Performance

In 2023, Recordati Industria Chimica e Farmaceutica's revenue was 2.08 billion, an increase of 12.36% compared to the previous year's 1.85 billion. Earnings were 389.21 million, an increase of 24.61%.

Financial numbers in EUR